UUDA.F Syntara Limited
- Market cap
- EUR 10.8M
- P/E
- -
- P/B
- 2.16x
- ROE
- -55.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is UUDA.F undervalued?
Graham numberThe Graham number of Syntara Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Syntara Limited fundamental analysis
No fundamental analysis for Syntara Limited yet.
Syntara Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Syntara Limited
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysp…
Full company profileSyntara Limited financial statements
Syntara Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 7.43M | 5.77M | - | - | - |
| Gross Profit | 7.43M | 3.06M | - | - | - |
| Operating Income | -22.8M | -25.3M | -19.5M | -19.9M | -16.6M |
| EBITDA | -12.2M | -9.29M | -13.0M | -12.0M | -9.46M |
| Net Income | -1.94M | -11.4M | -15.1M | -7.92M | -9.00M |
| EPS | 0.00 | -0.02 | -0.01 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 27.4M | 24.0M | 10.4M | 21.4M | 19.1M |
| Total Liabilities | 14.4M | 14.5M | 5.70M | 5.43M | 2.92M |
| Shareholders' Equity | 10.8M | 9.56M | 4.68M | 16.0M | 16.2M |
| Cash & Short-term Investments | 8.94M | 9.23M | 3.52M | 15.1M | 13.6M |
| Cash Flow | |||||
| Capital Expenditure | 307K | 138K | 7.00K | 0.00 | 2.00K |
| Free Cash Flow | -16.4M | -7.42M | -14.5M | -11.1M | -9.78M |
| Ratios | |||||
| ROE | -17.9% | -118.8% | -323.5% | -49.4% | -55.5% |
| ROA | -7.1% | -47.3% | -145.9% | -36.9% | -47.0% |
| Net Profit Margin | -26.1% | -197.1% | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Syntara Limited dividends
Syntara Limited has not paid dividends in the last 5 fiscal years.
Who owns Syntara Limited
- Insiders 29.00%
- Institutions 18.10%
- Public & others 52.90%
- Shares outstanding 1.96B
- Free float 1.52B
Syntara Limited company profile
- Company name
- Syntara Limited
- Ticker
- UUDA.F
- ISIN
- AU0000312480
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Fiscal year end
- June
- Address
- 20A Rodborough Road, Frenchs Forest, NSW, Australia, 2086
- Phone
- 61 2 9454 7200
- Website
- syntaratx.com.au
About Syntara Limited
Syntara Limited, a clinical-stage drug development company, that targets extracellular matrix dysfunction through amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis in Australia. Its lead product candidate is amsulostat, which has completed Phase 2a clinical trial for the treatment of bone marrow cancer myelofibrosis, as well as in Phase 1c/2 clinical trial for patients with myelodysplastic syndrome and in Phase 1/2 clinical trial to treat pancreatic cancer. The company also develops topical pan-LOX inhibitors with SNT-9465, which is in a Phase 1a/b study for hypertrophic scars; SNT-6302 for the treatment of keloid scars; and SNT-4728 to treat sleep behaviour disorders and slow progression of neurodegenerative diseases by reducing neuroinflammation. In addition, it develops other drug candidates to treat fibrotic and inflammatory diseases, including kidney fibrosis, MASH, pulmonary fibrosis, and cardiac fibrosis. The company has a collaboration agreement with the University of Western Australia to studying SNT-6302 in keloid scars. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.
Syntara Limited management
7- Mr. Gary Jonathan Phillips BPharm, MBACEO, MD & Director · born 1961
- Dr. Wolfgang G. Jarolimek B.Sc. Ph.D., Ph.D.Head of Drug Discovery · born 1964
- Ms. Kristen Morgan B.Sc., MMedSc, PGDipBusAdminHead of Medical & Regulatory Affairs - Alliance Management · born 1972
- Dr. Jana BaskarChief Medical Officer
- Mr. Timothy Luscombe B.Com., C.A.CFO & Company Secretary
- Mr. Cameron David Billingsley BA, LLB (Hons.)General Counsel · born 1977
- Dr. Dieter HamprechtHead of Chemistry